Cargando…
Systematic Review of Recurrent Osteosarcoma Systemic Therapy
SIMPLE SUMMARY: Osteosarcoma is the most common primary bone cancer. Its therapeutic approach includes cytotoxic chemotherapy and surgery. However, when recurrence or metastasis occurs the therapeutic options are limited with poor results. Herein we have conducted a systematic review of the systemic...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067690/ https://www.ncbi.nlm.nih.gov/pubmed/33917001 http://dx.doi.org/10.3390/cancers13081757 |
_version_ | 1783682861458522112 |
---|---|
author | Gazouli, Ioanna Kyriazoglou, Anastasios Kotsantis, Ioannis Anastasiou, Maria Pantazopoulos, Anastasios Prevezanou, Maria Chatzidakis, Ioannis Kavourakis, Georgios Economopoulou, Panagiota Kontogeorgakos, Vasileios Papagelopoulos, Panayiotis Psyrri, Amanda |
author_facet | Gazouli, Ioanna Kyriazoglou, Anastasios Kotsantis, Ioannis Anastasiou, Maria Pantazopoulos, Anastasios Prevezanou, Maria Chatzidakis, Ioannis Kavourakis, Georgios Economopoulou, Panagiota Kontogeorgakos, Vasileios Papagelopoulos, Panayiotis Psyrri, Amanda |
author_sort | Gazouli, Ioanna |
collection | PubMed |
description | SIMPLE SUMMARY: Osteosarcoma is the most common primary bone cancer. Its therapeutic approach includes cytotoxic chemotherapy and surgery. However, when recurrence or metastasis occurs the therapeutic options are limited with poor results. Herein we have conducted a systematic review of the systemic treatment options in recurrent and/or metastatic osteosarcoma over the last two decades. Our results indicate the paucity of our therapeutic armamentarium for this entity, with the majority of the studied modalities resulting in limited or no benefits. Intense translational research and future clinical studies reveal the unmet need for new treatment options for osteosarcoma patients with metastatic and/or recurrent disease. ABSTRACT: Osteosarcoma is the most frequent primary bone cancer, mainly affecting those of young ages. Although surgery combined with cytotoxic chemotherapy has significantly increased the chances of cure, recurrent and refractory disease still impose a tough therapeutic challenge. We performed a systematic literature review of the available clinical evidence, regarding treatment of recurrent and/or refractory osteosarcoma over the last two decades. Among the 72 eligible studies, there were 56 prospective clinical trials, primarily multicentric, single arm, phase I or II and non-randomized. Evaluated treatment strategies included cytotoxic chemotherapy, tyrosine kinase and mTOR inhibitors and other targeted agents, as well as immunotherapy and combinatorial approaches. Unfortunately, most treatments have failed to induce objective responses, albeit some of them may sustain disease control. No driver mutations have been recognized, to serve as effective treatment targets, and predictive biomarkers of potential treatment effectiveness are lacking. Hopefully, ongoing and future clinical and preclinical research will unlock the underlying biologic mechanisms of recurrent and refractory osteosarcoma, expanding the therapeutic choices available to pre-treated osteosarcoma patients. |
format | Online Article Text |
id | pubmed-8067690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80676902021-04-25 Systematic Review of Recurrent Osteosarcoma Systemic Therapy Gazouli, Ioanna Kyriazoglou, Anastasios Kotsantis, Ioannis Anastasiou, Maria Pantazopoulos, Anastasios Prevezanou, Maria Chatzidakis, Ioannis Kavourakis, Georgios Economopoulou, Panagiota Kontogeorgakos, Vasileios Papagelopoulos, Panayiotis Psyrri, Amanda Cancers (Basel) Systematic Review SIMPLE SUMMARY: Osteosarcoma is the most common primary bone cancer. Its therapeutic approach includes cytotoxic chemotherapy and surgery. However, when recurrence or metastasis occurs the therapeutic options are limited with poor results. Herein we have conducted a systematic review of the systemic treatment options in recurrent and/or metastatic osteosarcoma over the last two decades. Our results indicate the paucity of our therapeutic armamentarium for this entity, with the majority of the studied modalities resulting in limited or no benefits. Intense translational research and future clinical studies reveal the unmet need for new treatment options for osteosarcoma patients with metastatic and/or recurrent disease. ABSTRACT: Osteosarcoma is the most frequent primary bone cancer, mainly affecting those of young ages. Although surgery combined with cytotoxic chemotherapy has significantly increased the chances of cure, recurrent and refractory disease still impose a tough therapeutic challenge. We performed a systematic literature review of the available clinical evidence, regarding treatment of recurrent and/or refractory osteosarcoma over the last two decades. Among the 72 eligible studies, there were 56 prospective clinical trials, primarily multicentric, single arm, phase I or II and non-randomized. Evaluated treatment strategies included cytotoxic chemotherapy, tyrosine kinase and mTOR inhibitors and other targeted agents, as well as immunotherapy and combinatorial approaches. Unfortunately, most treatments have failed to induce objective responses, albeit some of them may sustain disease control. No driver mutations have been recognized, to serve as effective treatment targets, and predictive biomarkers of potential treatment effectiveness are lacking. Hopefully, ongoing and future clinical and preclinical research will unlock the underlying biologic mechanisms of recurrent and refractory osteosarcoma, expanding the therapeutic choices available to pre-treated osteosarcoma patients. MDPI 2021-04-07 /pmc/articles/PMC8067690/ /pubmed/33917001 http://dx.doi.org/10.3390/cancers13081757 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review Gazouli, Ioanna Kyriazoglou, Anastasios Kotsantis, Ioannis Anastasiou, Maria Pantazopoulos, Anastasios Prevezanou, Maria Chatzidakis, Ioannis Kavourakis, Georgios Economopoulou, Panagiota Kontogeorgakos, Vasileios Papagelopoulos, Panayiotis Psyrri, Amanda Systematic Review of Recurrent Osteosarcoma Systemic Therapy |
title | Systematic Review of Recurrent Osteosarcoma Systemic Therapy |
title_full | Systematic Review of Recurrent Osteosarcoma Systemic Therapy |
title_fullStr | Systematic Review of Recurrent Osteosarcoma Systemic Therapy |
title_full_unstemmed | Systematic Review of Recurrent Osteosarcoma Systemic Therapy |
title_short | Systematic Review of Recurrent Osteosarcoma Systemic Therapy |
title_sort | systematic review of recurrent osteosarcoma systemic therapy |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067690/ https://www.ncbi.nlm.nih.gov/pubmed/33917001 http://dx.doi.org/10.3390/cancers13081757 |
work_keys_str_mv | AT gazouliioanna systematicreviewofrecurrentosteosarcomasystemictherapy AT kyriazoglouanastasios systematicreviewofrecurrentosteosarcomasystemictherapy AT kotsantisioannis systematicreviewofrecurrentosteosarcomasystemictherapy AT anastasioumaria systematicreviewofrecurrentosteosarcomasystemictherapy AT pantazopoulosanastasios systematicreviewofrecurrentosteosarcomasystemictherapy AT prevezanoumaria systematicreviewofrecurrentosteosarcomasystemictherapy AT chatzidakisioannis systematicreviewofrecurrentosteosarcomasystemictherapy AT kavourakisgeorgios systematicreviewofrecurrentosteosarcomasystemictherapy AT economopouloupanagiota systematicreviewofrecurrentosteosarcomasystemictherapy AT kontogeorgakosvasileios systematicreviewofrecurrentosteosarcomasystemictherapy AT papagelopoulospanayiotis systematicreviewofrecurrentosteosarcomasystemictherapy AT psyrriamanda systematicreviewofrecurrentosteosarcomasystemictherapy |